The LRC-TriCEPS technology was invented by Andreas Frei and Bernd Wollscheid from ETH Zurich who published the technology in Nature Biotechnology Nature Biotechnology (Frei et al.(2012) Nature Biotechnology 30:997-1001) and further developed it to HATRIC-LRC (Sobotzki et al. Nature Communications, volume 9, Article number: 1519 (2018) doi:10.1038/s41467-018-03936-z)
- Extracellular proteins
- Peptide ligands
- Engineered affinity binders
Dualsystems Biotech AG is a biotech company providing analytic services for protein-protein interactions.
If you are looking for the targets of your ligand – peptide, protein, antibody, and virus – that are relevant in the living organism, call us on +41 44 738 50 00 or fill in the form on the right hand. We will contact you to see how LRC-TriCEPS technology (ligand-receptor capture) can answer your questions.
LRC-TriCEPS is a novel approach enabling the identification of cell surface receptors and off-targets on living cells for a wide range of orphan ligands. Advantages of LRC-TriCEPS compared to other approaches:
- No genetic manipulation
- No hypothesis needed
- Targets are embedded in plasma membrane in their natural microenvironment
- Cells are alive during interaction
The TriCEPS-based ligand-receptor capture technology is now available at Dualsystems.